Ambulatory hysteroscopy and its role in the management of abnormal uterine bleeding

Natalie A M Cooper,1 Lynne L L Robinson,2 T Justin Clark3

ABSTRACT
Hysteroscopy is now an ambulatory procedure, having moved from a conventional day-case operating theatre environment to the outpatient clinic setting. Outpatient hysteroscopy can be used as a diagnostic test and as a therapeutic modality for women presenting with abnormal uterine bleeding. In many cases women can be diagnosed and treated efficiently during a single hospital appointment. This article reviews the development of ambulatory hysteroscopy and how it should optimally be performed and implemented. The contemporary role of this technology for investigating and treating women with abnormal uterine bleeding is then discussed.

HYSTEROSCOPY AND THE AMBULATORY SETTING
Hysteroscopy is defined as the direct endoscopic visualisation of the uterine cavity. It is one of the commonest procedures in contemporary gynaecological practice. Hysteroscopy was originally introduced as an adjunct to ‘D&C’ – dilatation of the cervix and curettage of the endometrium – to enhance the diagnosis of suspected uterine pathologies, mostly associated with some form of abnormal uterine bleeding (AUB). Improvements in optics and miniaturisation of endoscopes allowed instrumentation of the uterine cavity, under direct vision and without the need for blind dilatation of the cervix. In the light of these developments, the requirement for general anaesthesia has become outdated; pain from insertion of large diameter dilators and endoscopes can be avoided and the enhanced image quality means that investigation can be completed rapidly. Hysteroscopy can also be used to treat uterine disorders associated with AUB. Refinements in ancillary equipment and innovations in technology have allowed small-dimension operative systems to be developed that are suitable for routine use in ambulatory patients.

This review will discuss the rationale, requirements and relevance of ambulatory hysteroscopy in the diagnosis and treatment of AUB, the commonest presenting symptom in gynaecology. A related article on the place and potential of ambulatory hysteroscopy in reproductive health appeared in an earlier issue of this journal,1 so matters related to fertility will not be discussed here.

WHAT IS AMBULATORY HYSTEROscopy?
The terms ‘outpatient’, ‘office’ and ‘ambulatory’ are often used interchangeably. Ambulatory hysteroscopy as discussed here refers to an outpatient-based hysteroscopic procedure, performed within adapted hospital or community settings, where the patient remains conscious and walks in and out of the hospital.
Implementing Ambulatory Hysteroscopy

Close communication between health care professionals from the relevant disciplines, engagement with patients and involvement with clinical managers and health service commissioners are all necessary to implement ambulatory gynaecological services successfully. With regard to hysteroscopy and AUB, a good starting point is to ascertain current activity levels and practices, especially hospital bed use and use of theatre time. A clear vision of what the new ambulatory service aims to deliver should be formulated and projections regarding resources, infrastructure, training, capital and ongoing investments must be made. Forecasted income, cost savings and the need to transfer budgets will have to be considered together with time frames for implementation.

The main obstacle to ambulatory hysteroscopic interventions is procedural feasibility, particularly with regard to ensuring a good patient experience. This primarily concerns adequacy of pain control. An evidence-based guideline covering best practice in outpatient hysteroscopy (OPH) has been published by the Royal College of Obstetricians and Gynaecologists (RCOG) and is summarised in Box 1. This guidance focuses on diagnostic hysteroscopy, but much of its information is transferable to therapeutic hysteroscopic interventions in the ambulatory setting.

Since publication of the RCOG guidance in 2011 there has been increased interest in optimising patient experience and pain control. Whilst the use of paracervical and intracervical local anaesthesia has been shown in the past to reduce pain in diagnostic hysteroscopy, the transferability of the findings to modern OPH is contentious in view of the further miniaturisation of endoscopes, obviating the need for cervical dilatation, and the more widespread adoption of the vaginoscopic technique which avoids the use both of a speculum and a cervical tenaculum. There has been recent interest in the use of hysteroscopically-guided injection of local anaesthesia into the uterine body itself prior to outpatient hysteroscopic surgical interventions such as polypectomy and endometrial ablation. The effectiveness of such approaches requires more evaluation in clinical trials.

Most hospitals now provide ambulatory diagnostic hysteroscopy services and so have the necessary

Table 1 Factors influencing the change from day-case to ambulatory hysteroscopic services

<table>
<thead>
<tr>
<th>Influencing factors</th>
<th>Consequences leading to change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minimally invasive diagnosis</td>
<td>Outpatient testing with pelvic ultrasound and endometrial sampling</td>
</tr>
<tr>
<td>Emphasis on conservative surgery</td>
<td>Alternatives to more invasive, morbid procedures such as hysterectomy, requiring hospital admission</td>
</tr>
<tr>
<td>Technological advances</td>
<td>Endoscopic imaging; miniaturisation, digitalisation and portability of equipment</td>
</tr>
<tr>
<td>Benefits for patients and health services</td>
<td>See Table 2</td>
</tr>
<tr>
<td>Economic and political considerations</td>
<td>Scarcity of health care resources and capacity. Publications from the DH and the RCOG support local and community delivery of services</td>
</tr>
</tbody>
</table>

DH, Department of Health; RCOG, Royal College of Obstetricians and Gynaecologists.
infrastructure in place so that the extra costs needed to implement therapeutic hysteroscopic interventions can be reduced. Additional training will be required, but familiarity with diagnostic OPH and the relative simplicity of the operative procedures, combined with advances in available health technologies, should translate into minimal costs and delays in establishing therapeutic services. Training courses are available for use of the new devices using increasingly sophisticated, realistic and valid simulators.\textsuperscript{11,12}

THE ROLE OF AMBULATORIAL HYSTEROSCOPY IN AUB

Ambulatory hysteroscopy and diagnosis

AUB affects women of all ages and includes heavy menstrual bleeding (HMB), unscheduled or ‘intermenstrual’ bleeding (IMB) and postmenopausal bleeding (PMB). Evaluation of the uterine cavity in women with AUB is the commonest indication for hysteroscopy. The conditions for which it can be useful in diagnosis are shown in Table 3. This table follows the classification system for causes of AUB using the acronym ‘PALM-COEIN’, as recently accepted by the International Federation of Gynecology and Obstetrics (FIGO).\textsuperscript{13,14}

Heavy menstrual bleeding

HMB affects one in five women and leads to 21\% of gynaecological referrals from general practitioners.\textsuperscript{14,15} Investigation of HMB is important to exclude serious genital tract disease and to optimise patient outcomes by identifying any underlying pathologies (Table 3) and instituting the most effective and appropriate therapies for such underlying conditions.

A recent economic analysis modelling a variety of diagnostic tests and combination testing strategies found that OPH or OPH combined with endometrial biopsy (EB) were the most cost-effective options when the all strategies were compared to a strategy of ‘no investigation’, where women were simply treated with a levonorgestrel intrauterine system (LNG-IUS). Investigation of HMB based on OPH in a ‘one-stop’ ‘see and treat’ setting was also identified as the most cost-effective option for women with HMB wanting to retain their fertility and in women who were refractory to LNG-IUS treatment in primary care.\textsuperscript{16} Inevitably, such decision analyses cannot account for all the nuances of testing. For example, this model did not take account of the ability of transvaginal ultrasound scanning (TVS) to image the adnexa and wider pelvis. However, OPH does appear to have an integral role in the diagnostic work-up of HMB.

Intermenstrual bleeding

IMB is usually of benign origin and is commonly associated with exogenous contraceptive hormones or attributed to physiological causes. It is important to exclude cervical abnormalities such as polyps, cervicitis or neoplasia as well as excluding lower genital tract infection. The place of hysteroscopy in the routine diagnostic approach to IMB is unclear. If symptoms persist or if the IMB is heavy, especially in women aged over 45 years, then further endometrial evaluation is appropriate to diagnose the endometrial pathologies described in Table 3.

Postmenopausal bleeding

PMB is an important problem because it can be the first symptom of endometrial cancer and therefore

---

**Table 2** Relative merits and disadvantages of ambulatory compared with day-case hysteroscopic interventions

<table>
<thead>
<tr>
<th>Domain</th>
<th>Ambulatory</th>
<th>Day-case*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-operative work up</td>
<td>▶ Minimal</td>
<td>▶ Pre-operative medical assessment required</td>
</tr>
<tr>
<td>Patient-centred care</td>
<td>▶ No need to fast</td>
<td>▶ Fasting required</td>
</tr>
<tr>
<td>Safety</td>
<td>▶ Convenient – rapid recovery</td>
<td>▶ Choice of general anaesthesia to avoid peri-operative pain</td>
</tr>
<tr>
<td>Feasibility</td>
<td>▶ Procedures possible in women with significant medical co-morbidities precluding general anaesthesia</td>
<td>▶ Removes limitation of patient tolerability</td>
</tr>
<tr>
<td>Recovery</td>
<td>▶ Rapid recovery and discharge</td>
<td>▶ Typical postoperative stays &gt;4 hours</td>
</tr>
<tr>
<td>Postoperative care</td>
<td>▶ Availability of reclining chairs/hospital trolleys for a minority of cases</td>
<td>▶ Postoperative nausea and time to recover from anaesthesia</td>
</tr>
<tr>
<td>Clinical outcomes</td>
<td>▶ Minimal – contact phone numbers, regular analgesia</td>
<td>▶ Increased likelihood of overnight stay</td>
</tr>
<tr>
<td>Economic outcomes</td>
<td>▶ RCTs required. Data to date support comparable feasibility, and equivalent effectiveness</td>
<td>▶ Requirement to have someone at home overnight</td>
</tr>
<tr>
<td></td>
<td>▶ Selected procedures appear to be associated with acceptable patient experience and enhanced safety</td>
<td>▶ Additional risks of anaesthesia and surgical trauma in an anaesthetised patient</td>
</tr>
<tr>
<td></td>
<td>▶ Selected procedures appear to be associated with increased cost-effectiveness</td>
<td>▶ Reference standard to compare against. Most procedures feasible in an ambulatory setting are generally safe, feasible and effective as a day-case procedure</td>
</tr>
</tbody>
</table>

*In hospital setting with general or regional anaesthesia. RCT, randomised controlled trial.
Box 1 Key recommendations for best practice in outpatient hysteroscopy (adapted from Clark et al.)

1. All gynaecology units should provide a dedicated outpatient hysteroscopy service that is appropriately sized, equipped and staffed, and located outside the formal operating theatre setting. The health care professional(s) should have the necessary skills and expertise to carry out diagnostic and/or therapeutic outpatient hysteroscopy.

2. Written patient information should be provided before the appointment and consent for the procedure should be taken.

3. Women without contraindications should be advised to consider taking standard doses of non-steroidal anti-inflammatory drugs 1 hour before their appointment, but routine use of opiate analgesia should be avoided.

4. Routine cervical preparation before outpatient hysteroscopy should not be used unless dilatation beyond Hegar 6 is anticipated.

5. Miniature hysteroscopic systems (≤4 mm outer diameter) should be used for diagnostic outpatient hysteroscopy. Choice of hystroscope (e.g. flexible or rigid; 0° or fore-oblique distal lenses) should be left to the discretion of the operator.

6. Carbon dioxide or normal saline can be used as distension media for diagnostic outpatient hysteroscopy, but saline should be used for operative procedures.

7. Routine, blind cervical dilatation should be avoided.

8. Topical application of local anaesthetic to the ectocervix should be considered where a cervical tenaculum is necessary. Routine administration of intracervical or paracervical local anaesthetic should be used where larger diameter hysteroscopes are being employed (outer diameter >5 mm) and where the need for cervical dilatation is anticipated (e.g. cervical stenosis). Standard protocols regarding the type, maximum dosage and route of administration of anaesthesia should be implemented.

9. Conscious sedation should not be routinely used in outpatient hysteroscopic procedures.

10. Vaginoscopy (avoiding the use of a vaginal speculum or cervical instrumentation) should be the standard technique for outpatient hysteroscopy.

requires urgent referral for investigation and diagnosis. However, it is important to remember that the majority of women presenting with PMB will have a benign cause, with only a small number having premalignant hyperplastic or malignant disease. In contrast to the investigation of HMB and IMB, the initial diagnostic work up for PMB is standardised, with published guidelines directing best practice to detect or exclude endometrial cancer. Initial TVS measurement of endometrial thickness is generally recommended and has been shown to be the most cost-effective strategy. If TVS is abnormal (‘screen-positive’), further investigation, including hysteroscopy in most cases, is necessary to establish the pathology and to guide appropriate treatment.

Ambulatory hysteroscopy and treatment

Many of the pathologies diagnosed by ambulatory hysteroscopy are suitable for immediate treatment as part of the same hysteroscopic procedure (‘see and treat’). The categories of AUB are taken from those listed in Table 3.

AUB-endometrium (AUB-E)

The recommended first-line treatment for HMB in women not actively trying to conceive is insertion of an LNG-IUS. OPH can be useful at the time of fitting the LNG-IUS in women where insertion is anticipated to be difficult, for example, narrow cervix (some nulliparous women, previous deliveries by caesarean section, past cervical cone biopsy), adverse uterine anatomy (acute flexion/retroversion, presence of fibroids) or patient factors limiting access to the lower genital tract such as obesity, anxiety or limited mobility. In cases that have not responded to LNG-IUS treatment, OPH can provide valuable information regarding suboptimal placement of a device or the presence of focal pathologies, endometrial disease or cavity enlargement.

Endometrial ablation should be offered to women with AUB-E who are certain that they will not wish to conceive in the future and where the LNG-IUS is either not desired, ineffective, not tolerated or contraindicated. ‘Second-generation’ ablation techniques are technically easier and quicker to perform than the hysteroscopic (first-generation) ablative techniques, and are safer and more cost effective. Reviews have found no evidence of any difference between the two in terms of improvement in HMB or patient satisfaction. The short duration, miniaturisation and semi-automation of some second-generation techniques lends them to being performed in an outpatient setting. Trials have demonstrated comparable effectiveness of ambulatory treatment using local anaesthesia and traditional approaches under general anaesthesia, and good levels of acceptability.
Table 3 Potential causes of abnormal uterine bleeding described using the PALM-COEIN classification system

<table>
<thead>
<tr>
<th>Pathology</th>
<th>Description</th>
<th>Ambulatory test*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polyps (AUB-P)</td>
<td>Endometrial polyps are focal outgrowths that can occur anywhere within the uterine cavity.</td>
<td>OPH/SIS (TVS)</td>
</tr>
<tr>
<td>Adenomyosis (AUB-A)</td>
<td>Adenomyosis is the presence of heterotopic endometrial tissue within the myometrium.</td>
<td>MRI/TVS (OPH)</td>
</tr>
<tr>
<td>Leiomyoma (AUB-L) (also known as myoma or fibroids)</td>
<td>Benign smooth muscle tumours of the uterus.</td>
<td>Submucous fibroids (Grade 0–2) OPH/SIS/MRI (TVS) Fibroids (Grade 3–8) TAS and TVS/MRI (OPH)</td>
</tr>
<tr>
<td>Malignancy and hyperplasia (AUB-M)</td>
<td>Endometrial hyperplasia is a proliferation of endometrial glands with structural abnormalities and crowding and is considered atypical where glands exhibit cytological atypia. Endometrial stromal invasion is seen with malignancy.</td>
<td>EB/OPH+EB (TVS)</td>
</tr>
<tr>
<td>Coagulopathy (AUB-C)</td>
<td>Systemic disorders of haemostasis, with von Willebrand disease being the most common.</td>
<td>Haematological testing</td>
</tr>
<tr>
<td>Ovulatory dysfunction (AUB-O)</td>
<td>Ovulatory dysfunction tends to result in unpredictable timing of bleeding and variable flow. It may be caused by polycystic ovary syndrome, hypothyroidism, hyperprolactinaemia, mental stress, obesity, anorexia, weight loss, or extreme exercise.</td>
<td>TVS/biochemical endocrine testing</td>
</tr>
<tr>
<td>Endometrial (AUB-E)</td>
<td>Endometrial causes of AUB refer mainly to the condition previously known as ‘dysfunctional uterine bleeding’, which is a diagnosis of exclusion, used when no other identifiable cause can be found and usually manifesting as heavy menstrual bleeding. It also includes inflammation and infection of the endometrium which are more likely to manifest as intermenstrual bleeding.</td>
<td>TVS/EB/OPH</td>
</tr>
<tr>
<td>Iatrogenic (AUB-I)</td>
<td>Iatrogenic causes of AUB include hormonal medications (systemic or intrauterine) and other drugs associated with anticoagulant therapy.</td>
<td>–</td>
</tr>
<tr>
<td>Not yet classified (AUB-N)</td>
<td>The role of chronic endometritis, arteriovenous malformations and myometrial hypertrophy in the development of AUB is yet to be accurately defined and thus these conditions have been included in this group.</td>
<td>TVS/MRI/EB/microbiological swabs</td>
</tr>
</tbody>
</table>

*Ambulatory tests shown in parentheses are those that can be used to aid diagnosis of particular pathologies but are considered second best.

AUB, abnormal uterine bleeding; DB, hysteroscopically-directed biopsy; EB, endometrial biopsy; MRI, magnetic resonance imaging; OPH, outpatient hysteroscopy; SIS, saline infusion sonography; TAS, transabdominal ultrasound scan; TVS, transvaginal ultrasound scan.

there are no contraindications such as suspected endometrial disease or congenital or acquired anomalies causing significant cavity distortion. Furthermore, it is important to determine that there has been no unrecognised false passage or perforation following cervical dilatation. Current protocols utilise simple preoperative analgesia and local anaesthetic cervical blocks. More recently, local anaesthesia injected hysteroscopically into the uterine fundus has been used to try to reduce peri-operative pain. Some practitioners advocate concomitant placement of the LNG-IUS. The LNG-IUS can provide effective contraception, may enhance treatment efficacy post-ablation and can protect against endometrial hyperplasia in those women deemed to have risk factors. However, the increased cost, and risks of infection, rare systemic hormonal side effects or device embedment, mean that this should only be considered in specific circumstances and after thorough discussion and documentation of this ‘off-label’ usage, or within a research context. In women requiring contraception after endometrial ablation, all methods should be discussed including the use of concomitant ambulatory hysteroscopic sterilisation. Some data are available to support this approach but more information is required to evaluate its contraceptive efficacy and short-term infective morbidity.
developed. These integrate tissue cutting with aspiration, thereby obviating the need for separate tissue retrieval. Hysteroscopic morcellator systems require a specific hysteroscope with an offset eyepiece to allow the morcellator to be passed through the operating channel. Morcellators are available in a variety of sizes, with the smaller ones (hystroscope diameter <6.5 mm) being more suitable for use in the outpatient setting. The feasibility and simplicity of the technique has been demonstrated and a RCT comparing the speed, pain, acceptability and feasibility of hysteroscopic morcellation against bipolar electrosurgery has shown that polyp removal is quicker, less painful and more likely to be complete with the morcellator.40 41

AUB leiomyoma (AUB-L)

Submucous fibroids can be removed or ablated in the outpatient setting42 using bipolar electrosurgery, although this is only generally feasible with smaller Grade 0 (see Table 3 for grading) non-fundal lesions. The smallest diameter hysteroscopic morcellators most suited for use in a conscious outpatient will not cut through fibrous tissue, although slightly larger ones will. Traditional, larger diameter resectoscopes are advocated by some practitioners in an outpatient setting,43 but in general, given the vascularity of larger submucous (Grade 1) fibroids, the conventional operating theatre setting with general or regional anaesthesia is more appropriate. OPH is useful to diagnose submucous fibroids but also to allow the surgeon to plan how best to remove them surgically, for example, outpatient versus inpatient; needle electrode en bloc excision versus resection in chips versus morcellation; down-regulation with gonadotrophin-releasing hormone analogues or ulipristal acetate. There is currently some interest in incising the capsule of a detected Grade 1 or 2 submucous lesion at outpatient diagnosis, thereby ‘preparing’ the fibroid for later resection under anaesthesia, the hope being that a Grade 1 fibroid will be extruded into the uterine cavity by myometrial contraction, in effect turning it into an easier-to-resect Grade 0 fibroid. No data to support this approach are available, so it cannot be recommended at present.

AUB-malignancy and hyperplasia (AUB-M)

Ambulatory hysteroscopy can diagnose global or focal endometrial hyperplasia or malignancy44 45 and aid blind or directed EB. Directed biopsy can be achieved using hysteroscopic graspers or the newer morcellator. For blind biopsy of larger areas of the endometrial cavity, the H Pipelle® may be used. This is a 3.1 mm diameter suction biopsy cannula based on the well-established Pipelle that can be inserted through the inner sheath of a suitable hystroscope once the telescope has been removed. This avoids the need to traverse the cervical canal blindly after hysteroscopy, which can be a problem in a minority of cases.46

Endometrial hyperplasia is often found within polyps, so complete hysteroscopic removal of polyps is recommended for diagnosis and treatment, followed by progestogenic therapy and OPH endometrial surveillance as appropriate.8

CONCLUSIONS

Hysteroscopy has evolved from a reluctant diagnostic adjunct to the traditional diagnostic ‘D&C’, in hospital and under general anaesthesia, to a predominantly ambulatory procedure providing both diagnosis and treatment. This change has resulted from the development of pioneering technologies, patient demand, the drive of enthusiastic clinicians and the need to conserve scarce health care resources whilst improving clinical care. OPH is a key component of diagnosis in all types of AUB, allowing optimal treatment strategies to be employed, based on the underlying uterine pathology. AUB of endometrial origin (AUB-E), uterine polyps and small submucous fibroids can be treated at the time of hysteroscopic diagnosis, providing convenience to women, more rapid resolution of symptoms and enhanced efficiency of care. Outpatient ‘see and treat’ approaches are likely to be further promoted in the UK through more favourable reimbursement, replacing financial incentives that support outdated inpatient treatments. Reports from recent research are clarifying the role of OPH in the diagnosis and treatment of AUB. Advances in instrumentation such as the use of integrated, portable, battery-operated imaging (e.g. the Endosee® device) and improvements in pain management will enable ambulatory hysteroscopy for AUB to move increasingly into the community setting.

Twitter Follow Natalie Cooper at @docnamic and Justin Clark at @TJustinC

Competing interests T Justin Clark was a Consultant to Conceptus. He received honoraria from Hologic and Ethicon for clinician training which were paid into a charitable account to fund research. He has also received honoraria for lecturing from Nordic Pharma. He has received trial funding from Hologic and is currently a member of their European Advisory Board. He has received funding for travel and accommodation at national and international conferences from Ethicon, Hologic, Conceptus and Smith & Nephew. He has received research grants from Cytic (now Hologic) and Smith & Nephew.

Provenance and peer review Commissioned; externally peer reviewed.

REFERENCES


**JOURNAL REVIEW WRITERS**

The Journal regularly reviews articles from related publications and is looking to recruit more volunteers to compile these short reviews. For further information and/or to offer your services (at most once or twice a year) please e-mail your contact details to the Journal Editorial Office together with a note of any special interests and/or expertise to assist us in allocating relevant articles to individual reviewers. For further information on this role please contact the Journal Editorial Office at journal@fsrh.org.